Safety & Pharmacokinetics of Pegolsihematide for Treatment of Anemia Patient With Myelodysplastic Syndromes
Status:
Unknown status
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
The primary objectives of the trial are to assess the safety and pharmacokinetics profile of
pegolsihematide for treatment of anemia patient with myelodysplastic syndromes.